Furthermore, Hu et al. found in their study that inhibition of PRMT5 by shRNA or pharmacological approaches attenuated tumor progression and caused enhanced PD-L1 expression and improved response to immune checkpoint inhibitors [50]. The gene discussed is CD274; the disease is neoplasm.